Treatment Action Group (TAG) released the latest installment of its 2026 Pipeline Report series on TB Vaccines, written by TB ...

Researchers discovered a previously unknown pathway that helps HIV stay hidden in the body, even when patients are taking ...

Dr Fiona Creswell, a physician and clinical researcher at the MRC/UVRI & LSHTM Uganda Research Unit explores what the IMPALA trial tells about the potential of long-acting HIV treatment in Africa, and ...

Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.

In previously untreated adults with HIV-1, initiating therapy with either DOR/ISL or BIC/FTC/TAF results in comparable enhancements in overall health status.

Older HIV patients with metabolic comorbidities who transition to a single-tablet BIC/LEN experience low rates of severe adverse events and treatment discontinuations.

Recombinant zoster vaccination may reduce incident heart failure risk in adults with HIV, providing a protective effect against risks heightened by herpes zoster.

Children were twice as likely to begin and complete the HPV vaccine series at clinics that began recommending it at ages 9 and 10 instead of ages 11 and 12, according to findings presented at IDWeek ...

GSK press release. GSK plc announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B virus infection in ...

AVAC, Access Bridge call for accelerated ambition to reach at least three million people with lenacapavir for HIV prevention by the end of 2027.

ViiV Healthcare announced evidence from the OPERA observational cohort spanning five years of real-world use of Cabenuva (long-acting cabotegravir and rilpivirine [CAB+RPV LA]) for HIV treatment in ...

By 2040, nearly half of people with HIV will be older than 65, and their Medicare costs could reach $200 billion, models project.